The US FDA has approved AstraZeneca’s Seroquel XR for the Treatment of Bipolar Depression and Bipolar Mania in the US
Filed under: Uncategorized | Tagged: 5-HT2, 5HT2, antagonist, Astellas, Astrazeneca, Dopamine D2, quetiapine, Seroquel | Leave a Comment »
The CHMP has recommended European approval of Olanzapine Long-acting Injection (Zypadhera) for maintenance treatment of patients with schizophrenia
Filed under: Uncategorized | Tagged: 5-HT2, 5HT2, antagonist, Dopamine, Lilly, olanzapine, olanzapine LAI | Leave a Comment »
Alexza has initiated a second Phase III trial of AZ-004 (Staccato, loxapine) for the treatment of acute agitation in patients with schizophrenia or bipolar disorder.
Filed under: gpcr | Tagged: 5-HT2, 5HT2, antagonist, AZ-004, AZ004, D2, Dopamine, Dopamine D2, loxapine, Staccato | Leave a Comment »
AstraZeneca have submitted a European application for Seroquel (quetiapine fumarate) extended release Tablets for the treatment of major depressive disorder
Filed under: gpcr | Tagged: 5-HT2, 5HT2, antagonist, Astellas, Astrazeneca, Dopamine D2, quetiapine, Seroquel | Leave a Comment »
The FDA has approved Seroquel (quetiapine fumarate) for the maintenance treatment of patients with bipolar I disorder. Seroquel is already approved by the FDA for the treatment of schizophrenia
Filed under: gpcr | Tagged: 5-HT1A, 5-HT2, 5HT1A, 5HT2, Alpha 1 Adrenoceptor, Alpha 2 Adrenoceptor, antagonist, Approval, Astrazeneca, Dopamine D1, Dopamine D2, gpcr, Histamine H1 | Leave a Comment »
AstraZeneca have submitted a supplemental NDA for Seroquel XR for the Treatment of Generalised Anxiety Disorder (GAD). The drug is already launched for Bipolar disorder and Schizophrenia.
Filed under: gpcr | Tagged: 5-HT1A, 5-HT2, 5HT1A, 5HT2, Alpha 1 Adrenoceptor, Alpha 2 Adrenoceptor, antagonist, Astrazeneca, Dopamine D1, Dopamine D2, Histamine H1 | Leave a Comment »
